Autopsy report · NCT05265728

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

“Due to sponsor decision, not for efficacy or safety reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 21 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Biogen

Sponsor type

Industry

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

Natalizumab

Participants

21

Sites

12

Countries

Japan

Trials that died the same way

• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
  “Sponsor decision, not for safety reasons.” (82% match in meaning)
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
  “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” (81% match in meaning)
• Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
  “Sponsor decision (not related to safety, efficacy or quality).” (79% match in meaning)
• A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
  “The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons.” (78% match in meaning)
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.